Trial · NCT06658522
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
NCT06658522, Phase 4, Recruiting, Amsterdam UMC, location VUmc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE). Trials, record NCT06658522. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06658522
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
- NCT number
- NCT06658522
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Amsterdam UMC, location VUmc
- Conditions
- Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
- Interventions
- Sotatercept
- First posted
- 2024-10-26
- Last updated
- 2025-09-22
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Power per beat | From enrollment to end of study at 24 weeks | mean pulmonary arery pressure (mPAP) x stroke volume (SV) |
| Primary | Right ventricular pulmonary artery coupling | From enrollment to end of study at 24 weeks | End systolic elastance (Ees)/ Arterial elastance (Ea) as derived from pressure-volume loops using right heart catheterization |
| Secondary | Right ventricular end systolic volume | From enrollment to the end of study at 24 weeks | Right ventricular end systolic volume as measured by cardiac magnetic resonance imaging |
| Secondary | Right ventricular end diastolic volume | From enrollment to the end of study at 24 weeks | Right ventricular end diastolic volume as measured by cardiac magnetic resonance imaging |
| Secondary | Right ventricular ejection fraction | From enrollment to the end of study at 24 weeks | Right ventricular ejection fraction as measured by cardiac magnetic resonance imaging |
| Secondary | Right ventricular mass | From enrollment to the end of study at 24 weeks | Right ventricular mass as measured by cardiac magnetic resonance imaging |
| Secondary | Stroke volume | From enrollment to the end of study at 24 weeks | Stroke volume as measured by cardiac magnetic resonance imaging derived aortic flow |
| Secondary | Left ventricular end diastolic volume | From enrollment to the end of study at 24 weeks | Left ventricular end diastolic volume as measured by cardiac magnetic resonance imaging |
| Secondary | Left ventricular end systolic volume | From enrollment to the end of study at 24 weeks | Left ventricular end systolic volume as measured by cardiac magnetic resonance imaging |
| Secondary | Left ventricular ejection fraction | From enrollment to the end of study at 24 weeks | Left ventricular ejection fraction as measured by cardiac magnetic resonance imaging |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06658522
GET https://conductscience.org/api/trials/v1/NCT06658522/registered